What Just Happened in Autoimmune Medicine

A series of papers published in the New England Journal of Medicine across 2024–2026 have quietly shifted the ceiling of what’s possible in autoimmune disease treatment. Researchers at the University of Erlangen-Nuremberg and collaborating centres infused CD19-targeted chimeric antigen receptor (CAR) T cells into patients with refractory systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis — diseases that, until now, required lifelong immunosuppression with variable success.

The results in SLE patients were striking: prompt clinical and serologic remission, with patients tapering off all conventional immunosuppressants. This isn’t a new drug in the standard sense. It’s an attempt to use engineered immune cells to perform a “hard reset” on a misfiring immune system.

The Core Concept: Deep B-Cell Depletion and Immune Reset

Before understanding CAR-T therapy, you need to understand why B cells matter so much in autoimmunity.

In diseases like SLE and systemic sclerosis, autoreactive B cells produce antibodies directed against the body’s own tissues — anti-dsDNA, anti-Sm, anti-Scl70. Existing B-cell-targeting therapies like rituximab (anti-CD20) deplete B cells but leave behind long-lived plasma cells that continue producing these autoantibodies. The immune memory that drives autoimmunity persists.

CD19 is expressed more broadly than CD20 — it’s present on B cells at virtually every stage of development, including plasmablasts and some plasma cells. CAR T cells engineered to target CD19 can therefore achieve deeper, more comprehensive B-cell depletion than rituximab. The hypothesis is that eliminating the entire autoreactive B-cell compartment gives the reconstituting immune system a chance to reset without the autoimmune memory intact.

The Clinical Data

The most referenced case series involved 15 patients:

  • 8 patients with SLE
  • 3 patients with idiopathic inflammatory myositis
  • 4 patients with systemic sclerosis

All patients received a single infusion of autologous CD19 CAR T cells after preconditioning with fludarabine and cyclophosphamide.

SLE outcomes were the most compelling. Patients achieved remission by SLEDAI criteria, with normalization of complement levels and disappearance of anti-dsDNA antibodies. Multiple patients discontinued all immunosuppressive medications during follow-up.

Systemic sclerosis results were more variable. Patients with anti-Scl70 antibodies did not achieve complete serologic remission, suggesting the autoantibody-producing compartment in fibrotic autoimmune disease may be harder to fully deplete or that pathology extends beyond B-cell activity.

A separate NEJM Correspondence published in 2026 reported in vivo administration of CD19 CAR T-cell therapy (via viral vector rather than ex vivo cell manufacturing) in a refractory SLE patient — a step toward making this approach less logistically complex.

Why This Matters Beyond the Headlines

CAR T-cell therapy for cancer requires harvesting, engineering, and re-infusing a patient’s own T cells — a process that takes weeks, costs hundreds of thousands of dollars, and carries significant toxicity risks including cytokine release syndrome (CRS) and neurotoxicity.

For autoimmune patients, the risk-benefit calculus is different than in oncology. These are not terminal patients — they have conditions that may span decades. The fact that severe CRS and neurotoxicity appear to be less frequent in autoimmune applications (compared to haematological cancers) is encouraging, but the data set is still small.

The Nature Medicine review from 2026 contextualizing this landscape frames the trajectory clearly: this is a rapidly developing field moving from proof-of-concept case series toward structured trials, but it is not yet standard of care, even for the most refractory patients.

The Pharmacist’s Read

Several things stand out from a pharmacological standpoint:

1. The preconditioning regimen matters enormously. Fludarabine and cyclophosphamide are themselves immunosuppressive and carry significant toxicity. The decision to use them — and at what dose — shapes both the efficacy and the side-effect profile of the CAR-T infusion.

2. The durability question isn’t answered yet. How long does immune reset actually last? What happens when B cells reconstitute? Do autoantibodies return? The case series follow-up periods are relatively short.

3. In vivo administration is the future, but it’s early. If CAR T-cell manufacturing can be simplified to an in vivo viral delivery approach, access could improve dramatically. The 2026 NEJM Correspondence on in vivo CD19 CAR T in lupus is a signal worth watching.

4. Disease heterogeneity matters. SLE responded better than systemic sclerosis with anti-Scl70. This tells us that the pathophysiology of different autoimmune diseases — even within the same diagnostic category — may respond differently to B-cell depletion depth.

What This Means for Patients Today

This is not accessible therapy for most people with autoimmune disease today. It is being evaluated in clinical trials at academic centres, primarily for patients who have failed multiple lines of conventional therapy.

If you have refractory lupus, myositis, or systemic sclerosis and have failed biologics and conventional DMARDs, it is worth asking a rheumatologist at an academic medical centre whether clinical trial eligibility applies to you.

For the majority of autoimmune patients, this research matters not because it changes your treatment today, but because it confirms that the immune system can be reset — and that changes the long-term therapeutic horizon considerably.

Sources: Müller F et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. NEJM 2024; Mackensen A et al. NEJM 2024; Müller F et al. In Vivo CD19 CAR T-Cell Therapy for Refractory SLE. NEJM Correspondence 2026; Mackensen A. CAR T Cells — A New Horizon for Autoimmunity? NEJM Editorial 2024; Resetting autoimmune disease with CAR cell therapies, Nature Medicine 2026.